APTO News and Press, Aptose Biosciences Inc. From 05/04/20

May 4, 2020 FN Media Group Presents Financialmorningpost.com Market Commentary   New York, NY – May 4, 2020 – A new medical development is sweeping the country. Some may see it as controversial – but the studies don’t lie. It’...

The following slide deck was published by Aptose Biosciences Inc. in conjunction with this Read more ...

Shares of Aptose Biosciences (NASDAQ: APTO) were sinking 11.9% as of 3:13 p.m. EDT on Monday. The decline came after the company presented preliminary clinical data from an early-stage clinical study evaluating CG-806 in treating relapsed or refractory chronic lymphocytic leukemia (CLL)...

Aptose Biosciences ( APTO -10.5% ) slips on modestly higher volume on the heels of preliminary data from a Phase 1a/b clinical trial evaluating CG-806 patients with a range of blood cancers. The results were presented at the American Association for Cancer Research (AACR) Virtual Annua...

SAN DIEGO and TORONTO, April 27, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today presented the early clinical data on CG-806, the company&...

SAN DIEGO and TORONTO, April 24, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announce...

SAN DIEGO and TORONTO, April 21, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended March ...

In a relatively short span of time, Aptose ( APTO ) has gone from a little-known Canadian biotech toiling largely in obscurity to a promising name with wider sell-side coverage. That expanded interest isn’t unreasonable in my view, as promising (but very early) data have made an initi...

Aptose Biosciences Inc. (APTO) Q4 2019 Earnings Conference Call March 10, 2020 05:00 PM ET Company Participants Susan Pietropaolo - SMP Communications William Rice - Chairman, President & Chief Executive Officer Gregory Chow - Executive Vice President & Chief Financial O...

Aptose Biosciences (NASDAQ: APTO ): Q4 GAAP EPS of -$0.13 misses by $0.01 . More news on: Aptose Biosciences Inc., Earnings news and commentary, Healthcare stocks news, Read more ...